4-(2-甲酰基-4-(三氟甲基)苯基)哌嗪-1-羧酸叔丁酯 | 626219-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(2-甲酰基-4-(三氟甲基)苯基)哌嗪-1-羧酸叔丁酯
• 英文名称: 4-(2-formyl-4-(trifluoromethyl)phenyl)piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: 4-(2-formyl-4-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester；2-[4'-(tert-butoxycarbonyl)-1-piperazinyl]-5-trifluoromethyl-benzaldehyde；tert-butyl 4-(2-formyl-4-(trifluoromethyl)phenyl)piperazine-1-carboxylate；4'-(tert-butoxycarbonyl)-1-piperazinyl-5-trifluoromethyl-benzaldehyde；tert-butyl 4-[2-formyl-4-(trifluoromethyl)phenyl]piperazine-1-carboxylate
• CAS: 626219-95-2
• 化学式: C₁₇H₂₁F₃N₂O₃
• 分子量: 358.361
• InChiKey: SHMBSPFQSGKEQE-UHFFFAOYSA-N

物化性质

• 熔点：
  94-95 °C(Solv: hexane (110-54-3))
• 沸点：
  435.8±45.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 海关编码：
  2933599090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 4-(2-formyl-4-(trifluoromethyl)phenyl)piperazine-1-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-(2-formyl-4-(trifluoromethyl)phenyl)piperazine-1-carboxylate
CAS number: 626219-95-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H21F3N2O3
Molecular weight: 358.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-甲酰基-4-(三氟甲基)苯基)哌嗪-1-羧酸叔丁酯 在 titanium(IV) tetraethanolate 作用下， 以 四氢呋喃 、 乙醇 、 正戊烷 为溶剂， 反应 17.0h， 生成 4-{2-[(R)-2-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-propyl]-4-trifluoromethyl-phenyl}-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Practical Asymmetric Synthesis of α-Branched 2-Piperazinylbenzylamines by 1,2-Additions of Organometallic Reagents to N-tert-Butanesulfinyl Imines

  摘要：

  2-[4-(tert-Butoxycarbonyl)piperazinyl]benzylidene-tert-butanesulfinamides underwent nucleophilic 1,2-addition with different organometallic reagents to give highly diastereomerically enriched adducts. X-ray crystallography of the resulting alpha-branched N-Boc-2-piperazinylbenzyl-tert-butanesulfinamides confirms different mechanisms depending on the organometallic reagent used. Differential deprotection of the N-Boc and the tert-butanesulfinamides was investigated, and the dehydration byproducts have been identified and characterized. To avoid the formation of byproducts in the acidic deprotection step, the N-tert-butanesulfinamide group was converted to the corresponding N-tert-butanesulfonamide (Bus), which allowed for clean orthogonal deprotection. The efficient synthesis and deprotection of the N-Boc-2-piperazinylbenzyl-tert-butanesulfinamides herein described constitutes an attractive method for extensive structure-activity studies in the search for novel ligands of the human melanocortin 4 receptor.

  DOI：

  10.1021/jo051514p
• 作为产物：
  描述：

  2-氟-5-(三氟甲基)苯甲醛 、 N-Boc-哌嗪 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 10.0h， 以92%的产率得到4-(2-甲酰基-4-(三氟甲基)苯基)哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO
  [FR] LIGANDS DU RECEPTEUR DE LA MELANOCORTINE ET COMPOSITIONS ET METHODES ASSOCIEES

  摘要：

  化合物作为黑色素皮质激素受体配体，并在治疗基于黑色素皮质激素受体的疾病中具有用途。这些化合物具有以下结构（I）：（R4）s（R 2）n N〜X1-X2（CR1aCRlb）q 1〜N R1-lm 1 O R3（I），包括立体异构体，前药和其药用盐，其中m、n、q、s、R1、R1a、R1b、R2、R3、R4、X1、X2和X3如本文所定义。还公开了含有结构（I）化合物的药物组合物，以及与其使用相关的方法。

  公开号：

  WO2005040109A1

文献信息

• CHEMICAL COMPOUNDS 251
  申请人：Dakin Leslie

  公开号：US20110218182A1

  公开（公告）日：2011-09-08

  The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.

  该发明涉及化学式(I)的化合物及其盐。在某些实施例中，该发明涉及PIM-1和/或PIM-2以及/或PIM-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文披露的化合物的药物组合物，以及它们在预防和治疗PIM激酶相关疾病和疾病，特别是癌症中的用途。
• (2-苄基苯基)哌嗪衍生物及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN108299338B

  公开（公告）日：2021-09-28

  本发明公开了(2‑苄基苯基)哌嗪衍生物及其用途，以及包含该类化合物的药物组合物，它们可用于抑制5‑羟色胺再摄取。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在治疗中枢神经系统功能障碍，特别是情感障碍中的用途。
• Ligands of melanocortin receptors and compositions and methods related thereto
  申请人：Tucci C. Fabio

  公开号：US20050119252A1

  公开（公告）日：2005-06-02

  Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R 1 , R 1a , R 1b , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , X 1 , X 2 , X 3 , X 4 and Ar are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  这是一种功能为黑素皮质素受体配体的化合物，可用于治疗基于黑素皮质素受体的疾病。该化合物具有以下结构（I）：包括立体异构体，前药和其药学上可接受的盐，其中m，n，q，s，R1，R1a，R1b，R2，R3，R4a，R4b，R5a，R5b，X1，X2，X3，X4和Ar的定义如本文所述。还公开了含有结构（I）化合物的药物组成物，以及与其使用相关的方法。
• Chemical Compounds 251
  申请人：AstraZeneca AB

  公开号：US20150051185A1

  公开（公告）日：2015-02-19

  The invention relates to chemical compounds of formula I, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.

  本发明涉及公式I的化合物及其盐。在某些实施例中，本发明涉及PIM-1和/或PIM-2，以及/或PIM-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含本文所披露的化合物的制药组合物，以及它们在预防和治疗PIM激酶相关的疾病和状况，尤其是癌症方面的应用。
• [EN] FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] DÉRIVÉ TRICYCLIQUE CONDENSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 并三环类衍生物、其制备方法及其在医药上的应用
  申请人：SHENZHEN SALUBRIS PHARM CO LTD

  公开号：WO2022007866A1

  公开（公告）日：2022-01-13

  一种涉及化学药物技术领域的并三环类衍生物、其制备方法及其在医药上的应用。所述并三环类衍生物是蛋白聚糖酶2(ADAMTS-5，Aggrecanase-2)的抑制剂。一种包含这些化合物的药物组合物以及将该化合物用于制备治疗骨关节炎等疾病的药物中的用途。